Small-molecule inhibitors of BRAF (vemurafenib, dabrafenib, encorafenib) were developed and first studied in BRAF V600-mutant melanoma, demonstrating impressive overall response rates (ORRs) but short progression-free survival (PFS) due to rapid MAPK-pathway reactivation [6,7,8]. Here, BRAF is linked to melanoma.